1) Biocon and Pfizer Enter Into Global Commercialization Agreement (Pfizer Press Release).
Pfizer will have exclusive license to commercialize biocon’s biosimilar versions of Recombinant Human Insulin, Glargine , Aspart and Lispro (all are long/fast acting insulin analogs).
… Under the terms of the agreement, Pfizer will make upfront payments totaling $200 million. Biocon is also eligible to receive additional development and regulatory milestone payments of up to $150 million and will receive additional payments linked to Pfizer’s sales of its four Insulin biosimilar products across global markets….
2) Venus Remedies drug wins Australia, Ukraine patents (ET report).
3) Transfer of Manufacturing and Marketing Approval and Distribution Rights for the Anti-Allergic Drug “Intal®” (Sodium cromoglycate) (Press release)